Related Experiment Video

Updated: Sep 2, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

583

Three-year disease-free remission in a xeroderma pigmentosum patient after adjuvant anti-PD-1 therapy

Valerie Scheer1, Oliver Schmalz2, Percy Lehmann1

  • 1Department of Dermatology, Allergology and Dermatosurgery, Helios University Hospital Wuppertal, University Witten/Herdecke, Germany.

European Journal of Cancer (Oxford, England : 1990)
|August 4, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.3K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.5K

Related Experiment Videos

Last Updated: Sep 2, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

583
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.3K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

Trust in skincare and topical therapies in atopic dermatitis or psoriasis: a German cross-sectional study.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026

Treatment Preferences Among Systemic Therapy-Naïve Patients with Atopic Dermatitis or Psoriasis in Germany: A Multicentre Study.

Dermatology and therapy·2025

Avapritinib reduces symptoms and mast cell burden in systemic mastocytosis.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2025

[Trichophyton mentagrophytes ITS genotype VIII/Trichophyton indotineae in Germany-revisit after 5 years].

Dermatologie (Heidelberg, Germany)·2025

Feasibility of evaluating AI-enabled digital symptom monitoring in metastatic patients with NSCLC receiving pembrolizumab therapy: A German single-arm observational pilot study.

Digital health·2025

Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.

Blood neoplasia·2025

Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer.

European journal of cancer (Oxford, England : 1990)·2026

Clinically actionable genetic findings by exome sequencing performed for therapeutic purposes in children with very-high risk cancer included the MAPPYACTS study.

European journal of cancer (Oxford, England : 1990)·2026

Single-item measures of perceived side effect burden for people with cancer: A systematic scoping review.

European journal of cancer (Oxford, England : 1990)·2026

Refining neoplasm risk in DICER1-related tumor predisposition.

European journal of cancer (Oxford, England : 1990)·2026

Towards a more proportionate EU framework for low-intervention clinical trials: Lessons from the UK and Switzerland.

European journal of cancer (Oxford, England : 1990)·2026

Recent trends in childhood, teenage and young adult cancer incidence in England (2001-2020).

European journal of cancer (Oxford, England : 1990)·2026

Observation of electrically generated polaron-polaritons in a monolayer MoSe2 microcavity.

Science advances·2026

Solution-Processable Cross-Linked Liquid Crystal Nanoparticles Enable Security Inks for Programmable Luminescence Lifetime and Color Coding.

Small (Weinheim an der Bergstrasse, Germany)·2026

Characterization of 2,7,12,17-tetra-tert-butyl-porphycene and its Pd2+ complex: from synthesis to the photoexcited triplet state.

Physical chemistry chemical physics : PCCP·2026

Ultrafast Dynamics of Organic Exciton-Polaritons.

Nanophotonics (Berlin, Germany)·2026

Quantum Dynamics Simulations of Polariton Transport in a Bloch Surface Wave Cavity.

Nanophotonics (Berlin, Germany)·2026

Polaritonic Spectra of Optical Mie Voids.

Nanophotonics (Berlin, Germany)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us